

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 June 2020 (25.06.2020)



(10) International Publication Number
WO 2020/132269 A1

(51) International Patent Classification:

A61K 31/519 (2006.01) A61P 35/00 (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:

PCT/US2019/067521

(22) International Filing Date:

19 December 2019 (19.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/783,014	20 December 2018 (20.12.2018)	US
62/799,423	31 January 2019 (31.01.2019)	US
62/857,986	06 June 2019 (06.06.2019)	US
62/868,616	28 June 2019 (28.06.2019)	US
62/946,263	10 December 2019 (10.12.2019)	US

(71) Applicant: **KSQ THERAPEUTICS, INC.** [US/US]; 610 Main Street North, 4th floor, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **BRENNEMAN, Jehrod Burnett**; 10 Warren Rd., Marblehead, Massachusetts 01945 (US). **KRALL, Elsa Beyer**; 94 Amory Street, #2, Cambridge, Massachusetts 02139 (US). **SCHLABACH, Michael**; 301 Pleasant Street, Belmont, Massachusetts 02478 (US). **WYLIE, Andrew Alistair**; 133 Temple Street, Newton, Massachusetts 02465 (US).

(74) Agent: **COVERT, John M.** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, N.W., Washington, District of Columbia 20005 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS



I

(57) Abstract: The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X^1 , X^2 , X^{11} , X^{12} , R^1 , R^3 , R^5 , R^5 , R^6 , and R^7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.